NASDAQ: BLFS |
| Healthcare / Medical Devices & Instruments / USA |
15.72 | 0 | 0.00 | Vol 2.85M | 1Y Perf -64.59% |
Jun 24th, 2022 16:00 DELAYED |
BID | 15.51 | ASK | 15.72 | ||
Open | 15.87 | Previous Close | 15.72 | ||
Pre-Market | - | After-Market | 16.50 | ||
- - | 0.78 4.96% |
Target Price | 32.71 | Analyst Rating | Strong Buy 1.25 | |
Potential % | 108.08 | Finscreener Ranking | ★★★★+ 55.57 | |
Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | ★★★★+ 58.20 | |
Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★★★+ 56.03 | |
Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | — - | |
Price Range Ratio 52W % | 10.58 | Earnings Rating | Sell | |
Market Cap | 666.67M | Earnings Date | 11th Aug 2022 | |
Alpha | 0.03 | Standard Deviation | 0.22 | |
Beta | 1.99 |
Today's Price Range 15.5416.53 | 52W Range 10.4060.67 | 5 Year PE Ratio Range -35.60-13.70 |
Summary:
Buy
Technical Indicators: | Buy |
Moving Averages: | Buy |
Performance | |||
---|---|---|---|
1 Week | 14.00% | ||
1 Month | 26.37% | ||
3 Months | -24.64% | ||
6 Months | -61.53% | ||
1 Year | -64.59% | ||
3 Years | 3.42% | ||
5 Years | 557.74% | ||
10 Years | - |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -2.62 | |||
ROE last 12 Months | -3.95 | |||
ROA (5Y Avg) | -0.69 | |||
ROA last 12 Months | -3.46 | |||
ROC (5Y Avg) | -9.77 | |||
ROC last 12 Months | -3.74 | |||
Return on invested Capital Q | -1.40 | |||
Return on invested Capital Y | -2.83 | |||
Assets Turnover | 0.20 | |||
Receivables Turnover | 5.20 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-39.60 | ||||
1.22 | ||||
4.22 | ||||
176.90 | ||||
-28.90 | ||||
-0.35 | ||||
5.60 | ||||
11.28 | ||||
551.35M | ||||
Forward PE | 55.25 | |||
PEG | -3.96 |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
2.40 | ||||
3.40 | ||||
0.04 | ||||
0.05 | ||||
-4 059.60 | ||||
Leverage Ratio | 1.10 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
28.50 | ||||
-28.80 | ||||
-17.50 | ||||
-43.90 | ||||
-9.81 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
138.53M | ||||
3.27 | ||||
74.36 | ||||
66.74 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q01 2022 | -0.13 | -0.19 | -46.15 |
Q04 2021 | -0.07 | -0.32 | -357.14 |
Q03 2021 | 0.02 | -0.19 | -1 050.00 |
Q02 2021 | 0.03 | 0.00 | -100.00 |
Q01 2021 | -0.01 | 0.01 | 200.00 |
Q04 2020 | -0.02 | -0.01 | 50.00 |
Q03 2020 | -0.02 | -0.02 | 0.00 |
Q02 2020 | 0.00 | -0.01 | - |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
6/2022 QR | -0.09 | 0.00 | - |
9/2022 QR | -0.07 | - | - |
12/2022 FY | -0.39 | -200.00 | Negative |
12/2023 FY | 0.24 | -58.62 | Negative |
Next Report Date | 11th Aug 2022 |
Estimated EPS Next Report | -0.09 |
Estimates Count | 2 |
EPS Growth Next 5 Years % | 10.00 |
Volume Overview | |
---|---|
Volume | 2.85M |
Shares Outstanding | 42.41K |
Shares Float | 33.86M |
Trades Count | 13.34K |
Dollar Volume | 45.11M |
Avg. Volume | 431.57K |
Avg. Weekly Volume | 442.29K |
Avg. Monthly Volume | 419.62K |
Avg. Quarterly Volume | 432.79K |
BioLife Solutions Inc. (NASDAQ: BLFS) stock closed at 15.72 per share at the end of the most recent trading day (a 0% change compared to the prior day closing price) with a volume of 2.85M shares and market capitalization of 666.67M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 158 people. BioLife Solutions Inc. CEO is Michael Rice.
The one-year performance of BioLife Solutions Inc. stock is -64.59%, while year-to-date (YTD) performance is -57.82%. BLFS stock has a five-year performance of 557.74%. Its 52-week range is between 10.4 and 60.669, which gives BLFS stock a 52-week price range ratio of 10.58%
BioLife Solutions Inc. currently has a PE ratio of -39.60, a price-to-book (PB) ratio of 1.22, a price-to-sale (PS) ratio of 4.22, a price to cashflow ratio of 176.90, a PEG ratio of 2.32, a ROA of -3.46%, a ROC of -3.74% and a ROE of -3.95%. The company’s profit margin is -9.81%, its EBITDA margin is -17.50%, and its revenue ttm is $138.53 Million , which makes it $3.27 revenue per share.
Of the last four earnings reports from BioLife Solutions Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-0.09 for the next earnings report. BioLife Solutions Inc.’s next earnings report date is 11th Aug 2022.
The consensus rating of Wall Street analysts for BioLife Solutions Inc. is Strong Buy (1.25), with a target price of $32.71, which is +108.08% compared to the current price. The earnings rating for BioLife Solutions Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
BioLife Solutions Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
BioLife Solutions Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 12.67, ATR14 : 1.06, CCI20 : 252.64, Chaikin Money Flow : -0.11, MACD : 0.27, Money Flow Index : 77.67, ROC : 6.65, RSI : 60.66, STOCH (14,3) : 79.39, STOCH RSI : 1.00, UO : 53.44, Williams %R : -20.61), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of BioLife Solutions Inc. in the last 12-months were: Aby J. Mathew (Option Excercise at a value of $314 560), Aby J. Mathew (Sold 220 949 shares of value $9 284 693 ), Andrew G. Hinson (Sold 2 500 shares of value $111 275 ), Joseph Schick (Sold 3 250 shares of value $132 664 ), Karen Foster (Option Excercise at a value of $133 924), Karen Foster (Sold 102 931 shares of value $4 177 856 ), Marcus Schulz (Sold 16 317 shares of value $718 483 ), Michael Rice (Option Excercise at a value of $592 343), Michael Rice (Sold 382 515 shares of value $14 635 251 ), Roderick De Greef (Option Excercise at a value of $0), Roderick De Greef (Sold 259 400 shares of value $10 833 413 ), Sarah Aebersold (Sold 1 628 shares of value $64 081 ), Todd Berard (Option Excercise at a value of $107 027), Todd Berard (Sold 76 065 shares of value $2 921 098 ), Troy Wichterman (Sold 1 127 shares of value $21 496 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Strong Buy | Strong Buy | Strong Buy |
BioLife Solutions Inc is active in the healthcare segment. The company is engaged in the developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud, hosted biologistics cold chain management application for shippers. The company's product offerings include hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs.
CEO: Michael Rice
Telephone: +1 425 402-1400
Address: 3303 Monte Villa Parkway, Bothell 98021, WA, US
Number of employees: 158
Tue, 10 May 2022 16:37 GMT BioLife Solutions (BLFS) Gets a Buy Rating from KeyBanc
- TipRanks. All rights reserved.Mon, 25 Apr 2022 09:01 GMT Analysts Offer Insights on Healthcare Companies: BioLife Solutions (BLFS) and Citius Pharmaceuticals (CTXR)
- TipRanks. All rights reserved.Thu, 17 Mar 2022 14:28 GMT Analysts Opinions Are Mixed on These Healthcare Stocks: BioLife Solutions (BLFS), Avrobio (AVRO) and Stryker (SYK)
- TipRanks. All rights reserved.Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. CBOE EDGX Top real-time data for Premium users, NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Technology and data provided by TeleTrader. Conditions of Use. The regulations of the respective stock are to be observed. Copyright © 2022. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer. The Cryptocurrency Market real-time data provided by Cryptocompare.com
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.